Antibodies

A common misconception is that stronger is always better. However, Nuvia wPrime 2A Media, a weak anion exchange hydrophobic interaction (AEX-HIC) mixed-mode chromatography resin, has won over purification scientists. Read about diverse use cases for Nuvia wPrime 2A Media and see the data for yourself.

The Pioneer Platform features one of the largest functional antibody libraries available, utilizing SpyLock technology for rapid prototyping and screening of hundreds of bispecific antibodies, and TrailBlazer technology for efficient antibody format conversion. Together, these services provide a comprehensive and streamlined solution for researchers seeking to develop innovative biotherapeutic therapies.

Nuvia wPrime 2A Resin has MMAEX functionality with a weak anion exchanger. See data showing improved mAb and bsAb purification compared to traditional resins.

Follow the story of Evitria as it grows from a small Chinese hamster ovary (CHO) cell supernatant supplier to a global therapeutic antibody production company serving clients across the globe. Bio-Rad has partnered with Evitria at every stage of this remarkable journey and looks forward to supporting its continued success.

Modern chromatographic resins enable new strategies for downstream processing of bispecific antibodies. Watch this webinar to see case studies and workflows.

Bispecific antibodies pose unique challenges in downstream processing. See how impurities were efficiently removed by mixed-mode chromatography in this webinar.

In recent years, biologics — drugs derived from living culture systems — have become increasingly significant in the fight against a plethora of conditions. Unfortunately, the efficiency of these drugs comes at a cost. A daily dose of a biologic drug costs, on average, 22 times more than conventional small-molecule drugs. Therefore, biosimilars are developed to make them more accessible. Lung cancer is an example where the development of biosimilars could increase treatment options available for patients.

The current gold standard in monoclonal antibody purification for most researchers is affinity purification with Protein A or G followed by size exclusion chromatography (SEC). Although robust and highly effective, this workflow does have critical pain points and inefficiencies, leaving researchers to feel that they must oversee every step of their workflow, not leaving their chromatography system unattended for more than a few minutes.

Biotherapeutic antibody discovery is inherently challenging. Amongst the clinically proven technologies for antibody discovery is phage display — a technique utilized by one of the most recent and innovative solutions on the market: the Pioneer Antibody Discovery Platform.

In this case study, process chromatography application scientist Artur Stanczak presents a two-step mAb purification workflow, comparing multimodal resin alternatives used for the polishing step that occurs after protein A capture. The design of experiment (DOE) data presented characterizes the behavior of multiple mAbs with two different mixed-mode resins. The importance of scale, prior knowledge, and the stage of development will also be discussed. The results of both mixed-mode resin studies and the different DOE approaches demonstrate the ability to achieve high-purity products.